DIVERSE MULTIDRUG-RESISTANCE-MODIFICATION AGENTS INHIBIT CYTOLYTIC ACTIVITY OF NATURAL-KILLER-CELLS

被引:64
作者
CHONG, ASF
MARKHAM, PN
GEBEL, HM
BINES, SD
COON, JS
机构
[1] RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT IMMUNOL MICROBIOL, 1653 W CONGRESS PKWY, CHICAGO, IL 60612 USA
[2] RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT GEN SURG, CHICAGO, IL 60612 USA
[3] RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT OCLS IMMUNOL, CHICAGO, IL 60612 USA
[4] RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT PATHOL, CHICAGO, IL 60612 USA
关键词
MULTIDRUG RESISTANCE; P-GLYCOPROTEIN; NK CELL; CYTOTOXICITY; REVERSING AGENTS;
D O I
10.1007/BF01754414
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multidrug resistance (MDR) is the phenomenon in which cultured tumor cells selected for resistance to one chemotherapeutic agent simultaneously acquire resistance to several apparently unrelated drugs. MDR in tumor cells is associated with the over-expression of P-glycoprotein, an ATP-dependent cell-membrane transport molecule. P-glycoprotein is also expressed in several normal tissues but its physiological role(s) is unknown. We recently observed that a hierarchy of MDR-like activity exists among human peripheral blood lymphocytes in the order CD8>CD4>CD20 (cytoxic/suppressor T cells, helper T cells and B cells respectively). In this study, we report that natural killer (NK) cells also express MDR-like activity. This activity could be inhibited with verapamil or solutol HS-15, two agents that reverse MDR in tumor cells. These, and four additional reversing agents, were used to investigate the possible role of P-glycoprotein in NK cells. We observed that at 10% of their IC50, five of six reversing agents inhibited NK-cell-mediated cytotoxicity; at higher (but non-toxic) doses, all six agents were inhibitory. These data suggest that NK-cell-mediated cytotoxicity may require the functional expression of an efflux molecule similar or identical to P-glycoprotein.
引用
收藏
页码:133 / 139
页数:7
相关论文
共 27 条
  • [1] ISOLATION AND GENETIC-CHARACTERIZATION OF HUMAN KB-CELL LINES RESISTANT TO MULTIPLE-DRUGS
    AKIYAMA, SI
    FOJO, A
    HANOVER, JA
    PASTAN, I
    GOTTESMAN, MM
    [J]. SOMATIC CELL AND MOLECULAR GENETICS, 1985, 11 (02) : 117 - 126
  • [2] EXPRESSION AND ACTIVITY OF P-GLYCOPROTEIN, A MULTIDRUG EFFLUX PUMP, IN HUMAN HEMATOPOIETIC STEM-CELLS
    CHAUDHARY, PM
    RONINSON, IB
    [J]. CELL, 1991, 66 (01) : 85 - 94
  • [3] CHONG ASF, 1988, J IMMUNOL, V141, P4418
  • [4] COON JS, 1991, CANCER RES, V51, P897
  • [5] MULTIDRUG RESISTANCE ACTIVITY IN HUMAN-LYMPHOCYTES
    COON, JS
    WANG, YZ
    BINES, SD
    MARKHAM, PN
    CHONG, ASF
    GEBEL, HM
    [J]. HUMAN IMMUNOLOGY, 1991, 32 (02) : 134 - 140
  • [6] MULTIDRUG-RESISTANCE GENE (P-GLYCOPROTEIN) IS EXPRESSED BY ENDOTHELIAL-CELLS AT BLOOD-BRAIN BARRIER SITES
    CORDONCARDO, C
    OBRIEN, JP
    CASALS, D
    RITTMANGRAUER, L
    BIEDLER, JL
    MELAMED, MR
    BERTINO, JR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (02) : 695 - 698
  • [7] DRUG-RESISTANCE IN MULTIPLE-MYELOMA AND NON-HODGKINS LYMPHOMA - DETECTION OF P-GLYCOPROTEIN AND POTENTIAL CIRCUMVENTION BY ADDITION OF VERAPAMIL TO CHEMOTHERAPY
    DALTON, WS
    GROGAN, TM
    MELTZER, PS
    SCHEPER, RJ
    DURIE, BGM
    TAYLOR, CW
    MILLER, TP
    SALMON, SE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (04) : 415 - 424
  • [8] DARZYNKIEWICZ Z, 1982, CANCER RES, V42, P799
  • [9] DUVIE BG, 1988, BR J HEMATOL, V68, P203
  • [10] THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE
    ENDICOTT, JA
    LING, V
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1989, 58 : 137 - 171